Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations.

ABSTRACT:

Background

Patients with non-small-cell lung cancer (NSCLC) and cancer driver gene mutations are mainly treated with targeted therapy. Research into the application of neoadjuvant immunochemotherapy for these patients is active and ongoing. In this study, we assessed the feasibility and safety of immunochemotherapy as a neoadjuvant treatment in patients with stage III NSCLC with common cancer driver gene mutations.

Methods

This retrospective study enrolled patients who had stage III NSCLC with the results of driver mutation testing [including epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), c-ros proto-oncogene 1, receptor tyrosine kinase (ROS1), rearranged during transfection (RET), anaplastic lymphoma k

SUBMITTER: Yang Y 

PROVIDER: S-EPMC11921351 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature